Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine

0 Views • 08/28/25

Side Effects

Subscribers

At the now-canceled American Academy of Neurology (AAN) 2020 Annual Meeting, a number of analyses were scheduled to be presented on ubrogepant (Ubrelvy; Allergan), a recently approved agent for the acute treatment of migraine with or without aura in adults. One suggested that the agent has an increased likelihood of providing patients freedom from pain and symptoms associated with headache during headaches of mild pain intensity, while another assessed the impact an optional second dose of the anti-calcitonin gene-related peptide (CGRP) medicine.

That second analysis, conducted by Jessica Ailani, MD, FAHS, director, MedStar Georgetown Headache Center, and associate professor of neurology, MedStar Georgetown University Hospital, and colleagues, showed that ubrogepant is the first and only treatment to demonstrate statistically higher rates of pain freedom at second dose compared to placebo, without additional safety concerns identified.

To find out more about what the data show, how they should be interpreted clinically, and the significance of patients having success with a second dose, NeurologyLive connected virtually with Ailani to gain her perspective on the results.

Up next

Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine

Up next

Please note that if you are under 18, you won't be able to access this site.

Up next

Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine

Up next

Language